Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...
More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...
Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, according to a new survey that was published on Friday. The new ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...